Clinical Trials
11 trialsNCT03016871 2026-05-28
Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL
City of Hope Medical Center
Phase 2 Active not recruiting
NCT02227199 2025-11-18
BV-ICE
University of Washington
Phase 1/2 Completed
NCT00574496 2023-09-28
Combination Chemotherapy Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or High-Risk Primary Refractory Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT03077828 2023-06-02
Pembrolizumab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
Northwestern University
Phase 2 Unknown
NCT01026220 2022-04-28
Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin Lymphoma
Children's Oncology Group
Phase 3 Completed
NCT00302003 2021-03-30
Combination Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Lymphoma
Children's Oncology Group
Phase 3 Completed
NCT00381940 2021-03-24
Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Therapy
National Cancer Institute (NCI)
Phase 2 Completed
NCT01169636 2021-01-06
Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00601718 2017-05-25
Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma
University of Washington
Phase 1/2 Completed
NCT00255723 2016-02-01
Combination Chemotherapy and Radiation Therapy in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed or Refractory Hodgkin's Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00003631 2016-01-25
Chemotherapy Plus Radiation Therapy in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed